Financial Results Reveal Revenue Spike but bioAffinity Projects Lower 2025 Outlook bioAffinity Technologies reported a 270% revenue jump to $9.4 million in 2024, driven by CyPath Lung’s 1,400% order growth. However, the company expects 2025 revenue of $6–8 million after discontinuing unprofitable pathology services, despite expanded insurance coverage and federal healthcare access.4